# Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

> **NCT02889796** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 1759 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Filgotinib
- **DRUG:** Placebo to match filgotinib
- **DRUG:** Adalimumab
- **DRUG:** Placebo to match adalimumab
- **DRUG:** MTX

## Key facts

- **NCT ID:** NCT02889796
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-30
- **Primary completion:** 2018-07-04
- **Final completion:** 2019-06-20
- **Target enrollment:** 1759 (ACTUAL)
- **Last updated:** 2021-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02889796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02889796, "Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02889796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*